A Biology That Moves
Female biology is not static. It shifts across the menstrual cycle, across the decade of perimenopause, and into the different physiological landscape of post-menopause [1]. These are not minor variations. Oestrogen and progesterone can change significantly within a single cycle, and those changes have downstream effects on nearly every physiological system [2].
When clinical care treats female biology as though it were constant, or as though it were simply a variation of male biology, the result is protocols that do not fit the physiology they are meant to support.
Oestrogen and Progesterone Across the Cycle
In the first half of the menstrual cycle, the follicular phase, oestrogen rises steadily. It drives energy, enhances mood, supports cognitive sharpness [3], and promotes the skin’s capacity to synthesise collagen [4]. Many women notice they feel at their best during this window.
After ovulation, the luteal phase begins. Progesterone becomes the dominant factor. It brings a calming, settling effect on the nervous system [5], but it also raises the body’s core temperature, slows gut motility, and can amplify sensitivity to stress. For some women, this phase comes with lower energy, appetite changes, or a tendency toward irritability and disrupted sleep [6].
These are not pathological responses. They are the product of a physiological environment that shifts meaningfully from one fortnight to the next. A clinical protocol that does not account for this is operating on incomplete information.
The Downstream Effects Women Notice
The effects of oestrogen and progesterone extend well beyond reproductive function.
Sleep quality is directly influenced by physiological status. Progesterone has a natural sedative-adjacent effect, mediated by its metabolite allopregnanolone acting on GABA-A receptors [5], which is why sleep often feels easier in the early luteal phase. But as progesterone declines toward the end of the cycle, and particularly during perimenopause when progesterone falls faster than oestrogen, sleep architecture can fragment significantly [6, 7].
Cognitive clarity fluctuates in step with physiological changes. Oestrogen supports neurotransmitter pathways involved in memory and executive function [3]. Women who notice sharper thinking in the first half of their cycle and foggier cognition in the luteal phase are not imagining the difference. There is emerging evidence suggesting a neurological basis for these experiences [8].
Skin integrity is also oestrogen-dependent. Oestrogen stimulates fibroblast activity and supports collagen synthesis [4]. As oestrogen levels decline in perimenopause, changes in skin thickness, moisture retention, and elasticity become more pronounced [9]. These are physiological outcomes of physiological change, not simply ageing in the general sense.
Metabolism responds to the physiological cycle, too. Insulin sensitivity changes across the month [10]. Energy utilisation shifts. Appetite regulation is influenced by both oestrogen and progesterone at different phases. A nutrition or protocol strategy that does not account for these cyclical shifts may produce inconsistent results, not because the approach is wrong, but because the timing is misaligned with the biology.
Sex-Specific Considerations in Research
The majority of clinical research, including research that underpins dosing guidelines and treatment protocols, has been conducted primarily on male subjects [11]. Where women are included, the data is rarely stratified by cycle phase, physiological status, or reproductive stage [12].
The consequence is a body of clinical literature that assumes a relatively stable physiological environment. In men, testosterone levels are generally consistent from day to day. In women, the physiological environment changes substantially across four weeks and changes again across years [1]. Applying dosing assumptions without considering sex-specific variables may not fully account for female physiology [13].
This is not a criticism of the research that exists. It is a recognition that female-specific clinical data remains underrepresented, and that practitioners who do not account for this gap are, by default, operating from an incomplete framework.
What Female-Specific Assessment Actually Examines
A female-first clinical assessment does not look at these factors in isolation. It examines cyclical patterns: where a woman is in her cycle, how her symptoms track across the month, what changes across phases, and what her physiological environment has looked like across recent years.
It considers life stage, because the physiological realities of a woman in her mid-thirties, a woman in perimenopause, and a post-menopausal woman are meaningfully different from each other. A protocol designed for one context will not necessarily serve another.
It looks at the whole physiological picture, not a single snapshot. Oestrogen and progesterone in relation to each other. Cortisol as a modifier of reproductive physiology. Thyroid function as a driver of metabolic baseline. These systems interact, and addressing one without understanding the others risks addressing the wrong variable.
Protocols Designed Around Female Reality
A protocol that accounts for female physiological reality does not apply a fixed daily framework without regard for cyclical variation. It considers what a woman’s physiological environment looks like across the month and designs around that variation rather than in spite of it.
It accounts for life stage transitions, particularly perimenopause, where physiological fluctuations become wider and less predictable before the sustained low-oestrogen environment of post-menopause settles in.
It is individually assessed, because even within the same life stage and cycle phase, two women will have different physiological baselines, different symptom profiles, and different priorities. Standardised templates exist because they are convenient. They are not because they are effective for individual biology.
Female-specific clinical care is not a premium add-on. It is what accurate prescribing for female physiology actually requires.
Individual results vary based on your unique biology and commitment to the program. Assessment findings do not guarantee a particular outcome.
This article is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare practitioner for advice specific to your circumstances.
References
- Prior JC. Perimenopause: the complex endocrinology of the menopausal transition. Endocrine Reviews. 1998;19(4):397-428. doi:10.1210/edrv.19.4.0341
- Sundstrom Poromaa I, Gingnell M. Menstrual cycle influence on cognitive function and emotion processing: from a reproductive perspective. Frontiers in Neuroscience. 2014;8:380. doi:10.3389/fnins.2014.00380
- Hara Y, Waters EM, McEwen BS, Morrison JH. Estrogen effects on cognitive and synaptic health over the lifecourse. Physiological Reviews. 2015;95(3):785-807. doi:10.1152/physrev.00036.2014
- Shah MG, Maibach HI. Estrogen and skin: an overview. American Journal of Clinical Dermatology. 2001;2(3):143-150. doi:10.2165/00128071-200102030-00003
- Schussler P, Kluge M, Yassouridis A, et al. Progesterone reduces wakefulness in sleep EEG and has no effect on cognition in healthy postmenopausal women. Psychoneuroendocrinology. 2008;33(8):1124-1131. doi:10.1016/j.psyneuen.2008.05.013
- Caufriez A, Leproult R, L’Hermite-Baleriaux M, Kerkhofs M, Copinschi G. Progesterone prevents sleep disturbances and modulates GH, TSH, and melatonin secretion in postmenopausal women. Journal of Clinical Endocrinology and Metabolism. 2011;96(4):E614-E623. doi:10.1210/jc.2010-2558
- Jehan S, Masters-Isarilov A, Salifu I, et al. Sleep disturbances across a woman’s lifespan: what is the role of reproductive hormones? Journal of Sleep Disorders and Therapy. 2015;4(4):1000209. PMID:37124413
- Henderson VW. Estradiol and cognitive function: past, present and future. Hormones and Behavior. 2014;66(4):602-618. doi:10.1016/j.yhbeh.2014.08.011
- Cauley JA. Estrogen and bone health in men and women. Steroids. 2015;99(Pt A):11-15. doi:10.1016/j.steroids.2014.12.010
- Yeung EH, Zhang C, Mumford SL, et al. Longitudinal study of insulin resistance and sex hormones over the menstrual cycle: the BioCycle Study. Journal of Clinical Endocrinology and Metabolism. 2010;95(12):5435-5442. doi:10.1210/jc.2010-0702
- Beery AK, Zucker I. Sex bias in neuroscience and biomedical research. Neuroscience and Biobehavioral Reviews. 2011;35(3):565-572. doi:10.1016/j.neubiorev.2010.07.002
- Zucker I, Prendergast BJ, Beery AK. Pervasive neglect of sex differences in biomedical research. Cold Spring Harbor Perspectives in Biology. 2022;14(4):a039156. doi:10.1101/cshperspect.a039156
- Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biology of Sex Differences. 2020;11(1):32. doi:10.1186/s13293-020-00308-5
